Search - tctmd.com

Displaying 1 - 20 of 94

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Polypills Added to List of WHO’s Essential Medicines

Michael O'Riordan

August 02, 2023

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Statins Are Cost-effective in the Elderly

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Bempedoic Acid Gains CV Risk Reduction Indication

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Less Is More: Lp(a) Much More Atherogenic Than LDL

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Polypills Added to List of WHO’s Essential Medicines

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content